Extendicare Inc.

LSE:0S9E Stock Report

Market Cap: CA$879.7m

Extendicare Valuation

Is 0S9E undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0S9E when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0S9E (CA$10.61) is trading above our estimate of fair value (CA$1.71)

Significantly Below Fair Value: 0S9E is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0S9E?

Key metric: As 0S9E is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0S9E. This is calculated by dividing 0S9E's market cap by their current earnings.
What is 0S9E's PE Ratio?
PE Ratio13.8x
EarningsCA$63.90m
Market CapCA$879.74m

Price to Earnings Ratio vs Peers

How does 0S9E's PE Ratio compare to its peers?

The above table shows the PE ratio for 0S9E vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average29.2x
CVSG CVS Group
22.5x15.5%UK£573.9m
SPI Spire Healthcare Group
31.3x26.9%UK£876.6m
MDC Mediclinic International
21.9x10.7%UK£3.7b
AMS Advanced Medical Solutions Group
41.2x23.0%UK£462.8m
0S9E Extendicare
13.8xn/aCA$879.7m

Price-To-Earnings vs Peers: 0S9E is good value based on its Price-To-Earnings Ratio (13.8x) compared to the peer average (31.5x).

Price to Earnings Ratio vs Industry

How does 0S9E's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0S9E 13.8xIndustry Avg. 18.8xNo. of Companies9PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0S9E is good value based on its Price-To-Earnings Ratio (13.8x) compared to the European Healthcare industry average (18.5x).

Price to Earnings Ratio vs Fair Ratio

What is 0S9E's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0S9E PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio13.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 0S9E's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0S9E forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$10.61
CA$10.50
-1.0%
7.8%CA$11.50CA$9.50n/a3
Nov ’25n/a
CA$9.67
0%
2.4%CA$10.00CA$9.50n/a3
Oct ’25CA$9.41
CA$9.67
+2.7%
2.4%CA$10.00CA$9.50n/a3
Sep ’25n/a
CA$9.50
0%
4.3%CA$10.00CA$9.00n/a3
Aug ’25n/a
CA$8.33
0%
2.8%CA$8.50CA$8.00n/a3
Jul ’25n/a
CA$8.33
0%
2.8%CA$8.50CA$8.00n/a3
Jun ’25n/a
CA$8.33
0%
2.8%CA$8.50CA$8.00n/a3
May ’25n/a
CA$8.00
0%
5.1%CA$8.50CA$7.50n/a3
Apr ’25n/a
CA$8.00
0%
5.1%CA$8.50CA$7.50n/a3
Mar ’25CA$6.79
CA$7.25
+6.8%
2.8%CA$7.50CA$7.00n/a3
Feb ’25CA$7.11
CA$7.25
+2.0%
2.8%CA$7.50CA$7.00n/a3
Jan ’25n/a
CA$7.25
0%
2.8%CA$7.50CA$7.00n/a3
Dec ’24n/a
CA$7.08
0%
6.0%CA$7.50CA$6.50n/a3
Nov ’24n/a
CA$7.00
0%
5.8%CA$7.50CA$6.50n/a3
Oct ’24n/a
CA$7.25
0%
3.4%CA$7.50CA$7.00CA$9.414
Sep ’24CA$6.45
CA$7.25
+12.4%
3.4%CA$7.50CA$7.00n/a4
Aug ’24CA$7.26
CA$7.25
-0.1%
3.4%CA$7.50CA$7.00n/a4
Jul ’24n/a
CA$7.25
0%
3.4%CA$7.50CA$7.00n/a4
Jun ’24n/a
CA$7.25
0%
3.4%CA$7.50CA$7.00n/a4
Mar ’24n/a
CA$7.13
0%
3.0%CA$7.50CA$7.00CA$6.794
Feb ’24n/a
CA$7.13
0%
3.0%CA$7.50CA$7.00CA$7.114
Jan ’24n/a
CA$7.25
0%
3.4%CA$7.50CA$7.00n/a4
Dec ’23CA$6.77
CA$7.25
+7.1%
3.4%CA$7.50CA$7.00n/a4
Nov ’23n/a
CA$7.56
0%
4.9%CA$8.00CA$7.00n/a4

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

0HG8

US$403.49

7D

0.4%

1Y

-15.5%

Kooth

UK£64.8m

Provides digital mental health services to children, young people, and adults in the United Kingdom.

KOO

UK£1.78

7D

7.6%

1Y

-40.4%

Enovis

US$2.7b

Operates as a medical technology company focus on developing clinically differentiated solutions worldwide.

0I1B

US$48.46

7D

9.7%

1Y

-3.3%